ClinicalTrials.gg
Not yet recruitingNCT06238934Updated Feb 2, 2024

Treatment of Knee Osteoarthritis With Bone Marrow Aspirate Matrix: Prospective, Randomized Trial

A Phase 3 interventional study of Bone marrow aspirate matrix and Bone marrow aspirate in Knee Osteoarthritis, sponsored by Instituto Nacional de Traumatologia e Ortopedia. Not yet recruiting at 1 site in Brazil. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Instituto Nacional de Traumatologia e Ortopedia · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Osteoarthritis, Knee with a site in Brazil — 12 open to participants now, 12 under way, 2 of them phase 3. Osteoarthritis, Knee · Brazil.

Planned enrollment
29th of 77
90 · median 66
Started
2024
with 6 others
Phase 3
8 of 79
2 open now
Primary completion
2025-03
later than 1 of 11 live
Registered
71st of 79
by date
Lead sponsor
2 of 79
Instituto Nacional de Traumatologia e Ortopedia

Among the 79 studies in Osteoarthritis, Knee with a site in Brazil, this one is the 29th largest by planned enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2024, is one of 8 in phase 3, reaches primary completion later than 1 of the 11 other live ones, and was the 71st registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 79 studies in Osteoarthritis, Knee with a site in Brazil are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Osteoarthritis, Knee with a site in Brazil, or all of them as a file.
02

Study summary

Knee osteoarthritis (KOA) first manifests itself as a molecular derangement followed by anatomical and/or physiological changes. Conservative treatment of osteoarthritis should be the first approach to patients with this disease. The interest in biological therapies, including viscosupplementation and cell therapy, involves the recent update in knowledge about the pathophysiology of OA and its natural history. The aim of the present study is to compare the clinical results of intra-articular hyaluronic acid infiltration (IHA), bone marrow aspirate (BMA) and BMA matrix in the treatment of knee osteoarthritis. The sample will consist of 90 patients with osteoarthritis of the knee followed up at the INTO, who will be divided into three groups: group A, treatment with BMA; group B, treatment with IHA ; and group C, treatment with BMA matrix. Patients will be submitted to clinical, subjective functional and radiographic evaluation by an observer independent of the one who applied the selected treatment, at moments before application and 3 months, 6 months and 12 months after application. We believe that treatment with BMA and the BMA matrix have a better effect in improving symptoms and for a longer period of time than treatment with hyaluronic acid.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • osteoarthritis
  • knee
  • hyaluronic acid
  • bone marrow aspirate
  • bone marrow aspirate matrix
04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Bilateral knee OA according to the American College of Rheumatology criteria Kellgren-Lawrence ≤ III in both knees Full range of movement (0 a 120°).

Exclusion criteria

Exclusion Criteria:

  1. history of trauma, infection or previous surgery in the affected limb two years before procedure (2)limb malalignment: varus> 10° or valgus >15° (3) 3 months before the procedure (4) viscosupplementation 12 months before procedure (5) inflammatory, rheumatological or disease (6) >35 kg/m2 (7) use of immunosuppresors or anticoagulants (8) active tumor (9) haematological disorder (10) Hip OA > Tonnis grade 3 (11) history of transmissible disease (12) patients unable for positioning for the procedure (13) patients living outside Rio de Janeiro metropolitan area
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Group A

    Bone marrow aspirate matrix

    Biological: Bone marrow aspirate matrix

  • Active comparator
    Group B

    Bone marrow aspirate

    Biological: Bone marrow aspirate

  • Active comparator
    Group C

    Hyaluronic acid

    Device: Hyaluronic acid

Interventions

  • BiologicalBone marrow aspirate matrix

    Bone marrow aspirate \* Hyaluronic acid

  • BiologicalBone marrow aspirate

    Bone marrow aspirate

  • DeviceHyaluronic acid

    Hyaluronic acid

06

What researchers measure

Primary outcomes

  1. Knee Society Score

    Time frame: before infiltration, 1 month after first infiltration, three months, six months and one year after infiltration

  2. Western Ontario and Mcmaster (WOMAC) score

    Time frame: before infiltration, 1 month after first infiltration, three months, six months and one year after infiltration

  3. Visual analog scale for pain

    Time frame: before infiltration, 1 month after first infiltration, three months after infiltration, six months and one year after infiltration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Mar 2025, 12 months later.

Of 36 non-industry phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 2, 2024
StartEst.
Mar 2024
Primary completionEst.
Mar 2025
CompletionEst.
Mar 2027
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06238934
Lead sponsor
Instituto Nacional de Traumatologia e Ortopedia
Responsible party
Eduardo Branco de Sousa (Orthopaedic surgeon, Instituto Nacional de Traumatologia e Ortopedia) — Principal investigator
First posted
Feb 2, 2024
Start date
Mar 2024 (estimated)
Primary completion
Mar 2025 (estimated)
Completion
Mar 2027 (estimated)
Last update
Feb 2, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion